Acute Flaccid Myelitis: Recent Progress in Epidemiology, Clinical Findings, Diagnosis, Therapeutic Approaches, and Future Outlooks

Q: What is the clinical evidence from this study?

Study design: Review. Population: Acute flaccid myelitis. Intervention: Supportive care and intensive rehabilitation. Primary outcome: Neurological and motor function recovery.

Ashish Jain

doi:10.62946/ijmphs/3.3.614-623

September 30, 2026International Journal of Medical Pharmaceutical and Health Sciences (IJMPHS).Open Access

Acute Flaccid Myelitis: Recent Progress in Epidemiology, Clinical Findings, Diagnosis, Therapeutic Approaches, and Future Outlooks

View Full Paper

Ask AI

Bookmark

Share

Key result

Acute flaccid myelitis yields meaningful motor recovery in only ~5% to 39% of patients.

Why the study?

No definitive prognostic variables or etiologies have been identified for acute flaccid myelitis, and treatment options remain limited with no clear consensus.

Key Points

To synthesize current evidence on the epidemiology, clinical presentation, diagnostic approaches, therapeutic strategies, and long-term outcomes of acute flaccid myelitis.
Literature review assessing published evidence on acute flaccid myelitis (AFM) pathogenesis and viral links to enterovirus D68 (EV-D68) and EV-A71.
Evaluated clinical interventions spanning respiratory support, pain management, physical rehabilitation, and investigational antiviral compounds.
AFM manifests with biennial surges in late summer and fall, with most pediatric cases developing muscle weakness and hyporeflexia or areflexia approximately 5 days after a prodromal infection.
Long-term motor recovery remains low; fewer than 10% of patients achieve complete neurological recovery, while 5% to 39% regain meaningful motor function.
No FDA-approved antiviral therapies exist, leaving airway management, nutritional interventions, and intensive physical rehabilitation as the primary effective standard of care.

Structured PICO

P

Population

Pediatric and adult patients (predominantly children under 10 years, median age 6.3 years) presenting with acute flaccid myelitis associated with non-polio enteroviruses such as EV-D68 and EV-A71.

I

Intervention

Supportive therapy (airway management, respiratory support, intensive rehabilitation, pain management, nutritional support) and experimental or off-label antiviral/immunomodulatory agents (fluoxetine, pleconaril, pocapavir, favipiravir, ribavirin, rupintrivir) or surgical treatments (tendon or nerve transfer).

O

Outcome

Neurological and motor function recovery, respiratory failure requiring mechanical ventilation, and long-term residual weakness or paralysis.

Limitations

No disease-specific antiviral or immunomodulatory medications have been proven effective in randomized clinical trials.
Viral RNA is frequently absent from cerebrospinal fluid at clinical presentation, limiting etiological confirmation.
Absence of central nervous system tissue specimens from affected patients hampers direct validation of neuropathogenesis in humans.
No definitive laboratory markers or prognostic variables have been identified to accurately predict long-term outcomes.
Absence of brain or spinal cord tissue specimens from affected patients hampers direct validation of pathogenesis in humans
Lack of direct viral isolation or genome identification from cerebrospinal fluid at clinical presentation complicates etiological confirmation
Cohorts studied for electromyography and nerve conduction study prognostic value are too small to make broad statements
No definitive prognostic variables or laboratory biomarkers have been identified to accurately predict long-term effects

Implication

This narrative review highlights the strong epidemiological link between Enterovirus D68 and acute flaccid myelitis, emphasizing that current management relies entirely on supportive care and rehabilitation due to the lack of proven antiviral therapies.

Abstract

Acute flaccid myelitis (AFM) is an uncommon neurological illness that first gained national recognition in 2014.This neurological condition manifests biennially, with peaks in even-numbered years.Most patients present in childhood, 5 days after a prodromal infection.In the summer and fall, patients typically observe muscle weakness and hypo-or areflexia.Clinical outcomes vary; however, most patients do not improve.No definitive prognostic variables or etiologies have been identified.However, enterovirus D68 (EV-D68) is suspected to contribute to AFM pathogenesis.Treatment options are limited, with no clear consensus.Supportive therapy has been the most successful so far.In our assessment of the literature, we highlight emerging evidence of a putative link between EV-D68 and AFM.In addition, we identify information gaps in AFM therapy and prognostic variables.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ashish Jain (2026) conducted a review in Acute flaccid myelitis. Supportive care and intensive rehabilitation was evaluated on Neurological and motor function recovery. Acute flaccid myelitis primarily linked to enterovirus D68 lacks proven targeted therapies, with supportive care and rehabilitation resulting in meaningful motor recovery in only 5-39% of patients.

synapsesocial.com/papers/6ae28e0ecbadf70daf6c3fe9 https://doi.org/10.62946/ijmphs/3.3.614-623

View Full Paper

Ask AI

Bookmark

Share

Acute Flaccid Myelitis: Recent Progress in Epidemiology, Clinical Findings, Diagnosis, Therapeutic Approaches, and Future Outlooks

Key Points

Structured PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Acute Flaccid Myelitis: Recent Progress in Epidemiology, Clinical Findings, Diagnosis, Therapeutic Approaches, and Future Outlooks

Key Points

Structured PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading